Australia’s economy under threat as national innovation slips yet again

By Peter Roberts Australia’s slide down the list of leading developed nations has been dramatically confirmed with the Australia Day weekend coinciding with evidence of a fall in our national innovation effort. The highly respected Bloomberg innovation index saw Australia slip to number 20 in the world on its ranking of innovation (table below). Australia…

First Graphene advances material processing understanding

Industrial materials producer First Graphene (ASX: FGR) has announced progress in its development of production processes used in making graphene oxide suitable for a number of industrial applications. Conventional processing to create dispersible graphene solutions utilise strong acids. First Graphene subsidiary 2D Fluidics Pty Ltd, Flinders University and the UK Graphene Engineering and Innovation Centre…

Interconnector likely to cut electricity costs

The Australian Energy Regulator (AER) has given approval for construction of an interstate electricity connector which has the potential of stimulating green-power investment and lowering eastern state power prices. The AER today approved the new South Australia-New South Wales interconnector, which will connect wind and solar production in South Australia with the east’s major electricity…

Bisalloy partners for market expansion

High strength steel manufacturer Bisalloy (ASX: BIS) is partnering with Singaporean/Chinese manufacturer Leong Jin (Changzhou) Special Steel to better penetrate Australian and South-East Asian steel markets. Bisdalloy will complement its range with Leong Jin product in Australia and the two companies will jointly pursue sales and distribution opportunities in Thailand, Indonesia and New Zealand. Bisalloy…

Anatara Lifesciences gets good news on GaRP supplement

Anatara Lifesciences (ASX:ANR) has released encouraging pre-clinical trial data of its Gastrointestinal ReProgramming (GaRP) dietary supplement which targets diarrhoea. The company is now targeting the second half of this year for human trials of GaRP which treats underlying causes such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). “Anatara believes its GaRP dietary…